CTNM - CIK 0001855175
The table below shows Contineum Therapeutics, Inc.'s balance sheet line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash & equivalents | $75.60M | $21.94M |
| Short-term investments | $187.29M | $182.82M |
| Receivables | - | - |
| Inventory | - | - |
| Total current assets | $267.92M | $206.39M |
| Property, plant & equipment | $830.00K | $989.00K |
| Goodwill | - | - |
| Total assets | $276.64M | $212.85M |
| Accounts payable | $1.02M | $1.81M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current liabilities |
| $9.74M |
| $9.97M |
| Long-term debt | - | - |
| Total liabilities | $15.65M | $14.78M |
| Retained earnings | -$177.38M | -$117.40M |
| Total equity | $260.99M | $198.07M |